Last edition
News about "COYA 302"
Coya Therapeutics Advances ALSTARS Trial into Active-Treatment Extension Phase
Coya Therapeutics announced that the first cohort of ALS patients in the ALSTARS trial has entered the 24-week blinded active-treatment extension phase, where all participants will receive COYA 302.
COYA 302 | 09/06/2026 | By News Bureau
Coya Therapeutics Wins FDA Fast Track for COYA 302 in Amyotrophic Lateral Sclerosis
Coya Therapeutics receives US Food and Drug Administration (FDA) Fast Track designation for COYA 302, an investigational biologic therapy for Amyotrophic Lateral Sclerosis (ALS).
COYA 302 | 13/05/2026 | By News Bureau | 148
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy